A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer.
about
Immunotoxin Therapies for the Treatment of Epidermal Growth Factor Receptor-Dependent CancersToxin-based targeted therapy for malignant brain tumorsGlypican-3 Targeting Immunotoxins for the Treatment of Liver CancerAdvances in anticancer immunotoxin therapyTargeted cytotoxic therapy kills persisting HIV infected cells during ARTSpheroids of HER2-Positive Breast Adenocarcinoma for Studying Anticancer Immunotoxins In Vitro.Elimination of murine and human T-cell epitopes in recombinant immunotoxin eliminates neutralizing and anti-drug antibodies in vivo.Neural stem cell therapy for cancer.Anti-tumor activity of an immunotoxin (TGFα-PE38) delivered by attenuated Salmonella typhimuriumElimination of tumorigenic human pluripotent stem cells by a recombinant lectin-toxin fusion proteinIn vitro and in vivo activity of the low-immunogenic antimesothelin immunotoxin RG7787 in pancreatic cancer.Channel-forming bacterial toxins in biosensing and macromolecule deliveryGPR107, a G-protein-coupled receptor essential for intoxication by Pseudomonas aeruginosa exotoxin A, localizes to the Golgi and is cleaved by furinAntibody phage display libraries: contributions to oncology.Toxin instability and its role in toxin translocation from the endoplasmic reticulum to the cytosol.Engineering toxin-resistant therapeutic stem cells to treat brain tumorsAntiviral activity of a single-domain antibody immunotoxin binding to glycoprotein D of herpes simplex virus 2.Combination treatments with the PKC inhibitor, enzastaurin, enhance the cytotoxicity of the anti-mesothelin immunotoxin, SS1P.Whole-genome RNAi screen highlights components of the endoplasmic reticulum/Golgi as a source of resistance to immunotoxin-mediated cytotoxicityMethylation-associated partial down-regulation of mesothelin causes resistance to anti-mesothelin immunotoxins in a pancreatic cancer cell line.Design and evaluation of a peptide-based immunotoxin for breast cancer therapeutics.Quantification of recombinant immunotoxin delivery to solid tumors allows for direct comparison of in vivo and in vitro results.Developing a Novel Gene-Delivery Vector System Using the Recombinant Fusion Protein of Pseudomonas Exotoxin A and Hyperthermophilic Archaeal Histone HPhA.Novel fusion proteins for the antigen-specific staining and elimination of B cell receptor-positive cell populations demonstrated by a tetanus toxoid fragment C (TTC) model antigen.Furin-dependent CCL17-fused recombinant toxin controls HTLV-1 infection by targeting and eliminating infected CCR4-expressing cells in vitro and in vivo.Gigantoxin-4-4D5 scFv is a novel recombinant immunotoxin with specific toxicity against HER2/neu-positive ovarian carcinoma cells.Selective killing of Kaposi's sarcoma-associated herpesvirus lytically infected cells with a recombinant immunotoxin targeting the viral gpK8.1A envelope glycoprotein.High throughput cytotoxicity screening of anti-HER2 immunotoxins conjugated with antibody fragments from phage-displayed synthetic antibody librariesIn vitro and in vivo antitumor effects of the recombinant immunotoxin IL6(T23)-PE38KDEL in multiple myelomaRecent Advances in the Development of Antineoplastic Agents Derived from Natural ProductsCombination treatments with ABT-263 and an immunotoxin produce synergistic killing of ABT-263-resistant small cell lung cancer cell lines.A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicityImmunogenicity of therapeutic recombinant immunotoxins.Anticancer Effects of Mesothelin-Targeted Immunotoxin Therapy Are Regulated by Tyrosine Kinase DDR1.The insulin receptor negatively regulates the action of Pseudomonas toxin-based immunotoxins and native Pseudomonas toxin.Anthrax toxin-mediated delivery of the Pseudomonas exotoxin A enzymatic domain to the cytosol of tumor cells via cleavable ubiquitin fusions.Protein Kinase Inhibitor H89 Enhances the Activity of Pseudomonas Exotoxin A-Based Immunotoxins.Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant ImmunotoxinsTumor therapy with a urokinase plasminogen activator-activated anthrax lethal toxin alone and in combination with paclitaxel.Immunotoxins: the role of the toxin.
P2860
Q26751473-505BF9AC-8E60-4609-97BB-2A7A75B0FFE0Q27006226-B115110F-7FA5-4722-985A-FB1689F406E9Q28077270-15F9E661-B96A-4A5F-AC22-98B44F67A7F2Q28085551-D6FBE520-EA43-484F-B471-0314456BE1F5Q28538598-7579ACBD-39CC-4A45-A8F8-5A361276F038Q33607808-1D92D4F6-883E-44CA-807F-463C9D6A6A9FQ33652098-26FB4621-4E71-484E-8626-7AAAB8F2BA7FQ33704489-AC24716A-9C98-41CE-9BBD-9AEB67061760Q33914020-2F56AFDA-CC82-43B3-8D2A-B9949E02278AQ34043742-E45DE836-1501-4FDD-A901-60739D0D9E15Q34080906-BA51F3D6-0397-4707-B67E-E07A4B0F7686Q34101821-5ABB81D1-FE4B-4F11-A486-B0EE4D2717DAQ34107128-79FB1068-BFBF-48B3-815D-A53818FFFD8EQ34323991-58BE8842-F37A-4011-BFC2-EECA5DFC38CCQ34426721-16316E93-ECF0-4B46-9109-5ABEFB0CEA21Q34444939-1200821A-9CCC-4CAC-B41D-34EF5D335DC3Q34923432-62905DC3-9CC9-49E0-A05B-421D89A382B5Q35018336-B7CC1F05-A724-4F35-A9C9-DCFD879052C1Q35189855-EEF9E4A4-B679-495B-BB42-D400198FDD54Q35214050-E56993BD-98AC-4883-BF0A-6C1F2A1715D6Q35244073-80F45984-DD23-44F2-BD24-645CBD67EE44Q35786026-A844EF88-F5F0-481C-AB6C-78202AE649C4Q35837728-5180E280-9C13-4BD4-AE09-F97DC28A9DC2Q35925459-594AE3D1-8EFB-4983-BC74-3902B2E43AE0Q35984815-6A53C503-C917-4A38-961F-4B6D91D64C9DQ35985081-DBBE8788-D7E8-49C0-9ECF-600C62CCA902Q35992503-203C0EC5-1897-4975-BE07-8CF0B2168E31Q36109883-FF3EDE92-B6D2-49D8-9F9D-513156FD0A43Q36110386-AE51F471-3AB4-43E6-8690-9FA8A5464E0DQ36273796-E07CC9FE-104A-42A4-A938-25DCA8E64859Q36481165-076E9588-63D8-40DC-81E9-49B1F2CBA921Q36536466-7566143C-7FCA-4704-BDC3-F84C3A68C536Q36593468-DDC9A4CA-B496-4075-867B-6BCBDE053BDFQ36693123-51CF6841-1542-4595-A4FF-FC62EDB6A355Q36745522-A69F8C06-0D64-43AB-B608-B1371FDB01C6Q36829224-4298C243-FACD-413F-96BC-5A6E5BF498CBQ36917916-5C2D492C-6C4D-4939-8DE1-351CA4703783Q37075257-AA5C9249-9EBB-4A06-9395-37AFF90D64ACQ37133208-E508DA66-4EED-4007-AB68-04BAD77F902FQ37139525-5B715106-10F3-4477-B1CB-E46113183A68
P2860
A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A guide to taming a toxin--rec ...... A for the treatment of cancer.
@ast
A guide to taming a toxin--rec ...... A for the treatment of cancer.
@en
type
label
A guide to taming a toxin--rec ...... A for the treatment of cancer.
@ast
A guide to taming a toxin--rec ...... A for the treatment of cancer.
@en
prefLabel
A guide to taming a toxin--rec ...... A for the treatment of cancer.
@ast
A guide to taming a toxin--rec ...... A for the treatment of cancer.
@en
P2860
P1433
P1476
A guide to taming a toxin--rec ...... A for the treatment of cancer.
@en
P2093
Ira Pastan
P2860
P304
P356
10.1111/J.1742-4658.2011.08182.X
P407
P577
2011-06-02T00:00:00Z